This is a working overview of HPLC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Medical uses == Vortioxetine is used as a treatment for major depressive disorder, with its effectiveness shown to be similar to other antidepressants and its effect size has been described as modest. Vortioxetine may be used when other treatments have failed. A 2017 Cochrane review on vortioxetine determined that its place in the treatment of severe depression is unclear due to low-quality evidence and that more studies comparing vortioxetine to selective serotonin reuptake inhibitors (SSRIs), the typical first-line treatments, are needed. Vortioxetine appears to work in depressed patients with anxiety. Vortioxetine is also used off label for anxiety. A 2016 review found it was not useful in generalized anxiety disorder at 2.5, 5.0, and 10 mg doses (15 and 20 mg doses were not tested). A 2019 meta-analysis found that vortioxetine did not produce statistically significant results over placebo in the symptoms, quality of life, and remission rates of generalized anxiety disorder, but it was well-tolerated. However, a 2018 meta-analysis supported use and efficacy of vortioxetine for generalized anxiety disorder, though stated that more research was necessary to strengthen the evidence. A 2021 systematic review and meta-analysis concluded that there was uncertainty about the effectiveness of vortioxetine for anxiety due to existing evidence being of very low-quality.
In the twenty-first century, donkey milk is largely used in the manufacture of soaps and moisturizers, but evidence shows it has possible medical uses to treat infants and children with cow's milk protein allergy (CMPA) as a natural "formula" for infants.
Prior to Ahmed's execution, the last judicial hanging for murder was carried out in 2019. As of November 2024, another eight traffickers, including Rosman Abdullah, Roslan Bakar and Pausi Jefridin, were hanged in Singapore after Ahmed.
Sources: en.wikipedia.org
=== Available forms === Suvorexant is available in the form of 5, 10, 15, and 20 mg oral film-coated tablets. It is provided as 10- and 30-tablet blister packs as well as 3-tablet starter packs. The availability of these different packs varies by country.
Ajahn Brahm agrees, writing that the main purpose of dependent origination is to explain "how there can be rebirth without a soul" and "why there is suffering, and where suffering comes to an end." Brahm cites the definitions of the nidanas in the Vibhaṅgasutta (SN 12.2) which clearly indicate that birth and death is meant literally. According to Brahm,Paṭicca-samuppāda shows the empty process, empty of a soul that is, which flows within a life and overflows into another life. It also shows the forces at work in the process, which drive it this way and that, even exercising sway in a subsequent life. Dependent origination also reveals the answer to how kamma done in a previous life can affect a person in this life. Brahm argues that there are two parallel processes at work in dependent origination (which are really one process looked at from different angles), one is delusion and kamma leading to rebirth consciousness (nidanas # 1 – 3) and the other is craving and clinging leading to existence and rebirth (# 8 – 11). Brahm describes this as follows: "deluded kamma and craving produce the fuel which generates existence and rebirth (into that existence), thereby giving rise to the start of the stream of consciousness that is at the heart of the new life." Furthermore, dependent origination explains rebirth without appeal to an unchanging self or soul (atman). Paul Williams sees dependent origination as closely connected with the doctrine of not-self (anatman) which rejects the idea there is an unchanging essence that moves across lives.
Sugar phosphates (sugars that have added or substituted phosphate groups) are often used in biological systems to store or transfer energy. They also form the backbone for DNA and RNA. Sugar phosphate backbone geometry is altered in the vicinity of the modified nucleotides. Examples include:
Sources: en.wikipedia.org
Whatever moral and religious interpretation one places upon it, the fall in Lynn clearly marked a turning point in [Eddy's] life, the moment when she began to take charge of her life... She herself consistently, and with increasing fervor and conviction, attributed that change to a new understanding of God's relation to the world, and to a new sense of her own special divine mission. Whether we label this delusion or revelation, the fact remains that the woman was fundamentally empowered, and that there was no external, material change to account for that increase of power.
==== Osteoma cutis ==== Osteoma cutis is a cutaneous condition characterized by the presence of bone within the skin in the absence of a preexisting or associated lesion. Osteoma cutis often manifests as solid, varying-sized, skin-colored subcutaneous nodules.
=== Gene therapy === Gene therapy was first trialled in 2014 on a single patient, and followed by clinical trials in which several patients were successfully treated. In 2023, both exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) were approved for the treatment of sickle cell disease. Kendric Cromer in October 2024 became the first commercial case in the US to receive gene therapy and was discharged from Children's National Hospital. The one-off gene-editing therapy, Casgevy, also known as Exa-cel, is to be offered to patients on the National Health Service (NHS) in England as from 2025. Both Casgevy and Lyfgenia work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel, the person with sickle cell disease's bone marrow undergoes a myeloablation procedure to destroy the remaining HSCs. The treated cells are then infused back into the patient, where they colonise the bone marrow and eventually resume production of blood cells. Casgevy works by editing the BCL11A gene, which normally inhibits haemoglobin F (foetal haemoglobin) production in adults. The edit increases HbF production, which is not prone to sickling. Lyfgenia introduces a new gene for T87Q-globin, which coexists with the sickling beta-globin but reduces the incidence of sickling. A study published in the New England Journal of Medicine in April 2026 showed a new CRISPR gene therapy labeled renizgamglogene autogedtemcel (abbreviated to reni-cel) that increased total hemoglobin from 9.8 to 13.8g/dL.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.